Plasma levels of soluble interleukin 2 receptor, soluble @entity5823 , XXXX and B cell activator of the @entity5 necrosis factor family during follow-up in @entity1333 associated with @entity7134 -antineutrophil cytoplasmic antibodies: associations with disease activity and relapse.

@entity1 @entity8410 @entity5 @entity1333 @entity5823 @entity7134 @entity688 @entity19417
OBJECTIVES: To evaluate whether T cell activation, as reflected by levels of soluble interleukin 2 receptor (sIL2R), soluble @entity5823 (sCD30), @entity688 and B cell activator of the @entity5 necrosis factor family ( @entity8410 ) at diagnosis and during initial follow-up, is predictive for persistent or renewed antineutrophil cytoplasmic antibody (ANCA) positivity and clinical relapse in @entity1 with @entity1333 associated with @entity7134 -antineutrophil cytoplasmic antibodies ( @entity7134 -ANCA). METHODS: 87 @entity1 with @entity7134 - @entity19417 and at least 2 years of follow-up were included in the study. At diagnosis, and at 3, 6, 12, 18 and 24 months after diagnosis, cytoplasmic ANCA titres were detected by indirect immunofluorescence (IIF), and @entity7134 -ANCA, sIL2R, sCD30, @entity688 and @entity8410 levels were assessed by ELISA. 31 healthy volunteers provided plasma samples for comparison. Levels of immune markers were related to ANCA positivity and relapse during follow-up. RESULTS: Plasma levels of sIL2R, sCD30 and @entity8410 were higher in @entity1 than in controls at all time points. Plasma levels of sIL2R, sCD30 and @entity688 were higher at diagnosis and relapse than during remission. At 18 months, sCD30 (p<0.001) and sIL2R levels (p = 0.01) were significantly higher in @entity7134 -ANCA-positive @entity1 (detected by ELISA) than in @entity7134 -ANCA-negative @entity1 . ANCA-positive @entity1 detected by ELISA or IIF at 24 months had significantly higher plasma sCD30 levels (p = 0.02 and p = 0.03, respectively) than ANCA-negative @entity1 . CONCLUSION: Increased T cell activation in @entity1 with @entity19417 in remission during and after immunosuppressive treatment is associated with persistent or renewed ANCA positivity.
